AZN to withdraw Iressa MAA

AstraZeneca (LSE:AZN; AZN) is withdrawing its MAA for Iressa gefitinib to treat non-small cell lung cancer (NSCLC)

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE